Abstract: | Vasovagal syncope (VVS), a clinical problem with highmorbidity, seriously affects patients' life style, therefore ap-propriate prophylaxis and treatment of VVS are imperative.Though β-blockers, theophylline, and scopolamine have sh-own curative effects on WS, their use are limited due to sideeffects. We hypothesize that irbesartan, an angiotensin Ⅱ rece-ptor antagonist, can be used to treat VVS with no limitationespecially in small dosage. |